Menu

Cancer Tissue Repository Launched

The Dana-Farber Cancer Institute will store tissue samples from patients with leukemia and lymphoma from which scientists can make patient-derived mouse models.

Apr 11, 2016
Jef Akst

WIKIMEDIA, RAMAOne method that is growing in popularity for testing drugs on specific cancer types is the creation of patient-derived xenografts (PDXs), in which researchers implant bits of cancerous tissue extracted from patients into mice for study. Today (April 11), the Dana-Farber Cancer Institute announced the launch of an open-source public repository of biopsy tissue collected from patients with leukemia and lymphoma. Researchers can register for the database, called the Public Repository of Xenografts (PRoXe), use its Web portal to search for PDX models of specific subtypes of blood cancers, and order frozen cells from which they can create xenograft mouse models.

“About 90 percent of compounds that show anti-cancer activity in pre-clinical tests don’t work when given to patients,” said Dana-Farber’s David Weinstock said in a press release. “By trying drugs in PDX models, we can ‘mimic’ large and expensive human clinical trials and get answers about efficacy more quickly, less expensively and without the need for patients to get investigational drugs that won’t work.” Weinstock and his colleagues published details of the new repository today (April 11) in Cancer Cell; a total of 95 different researchers from 14 institutions are listed as coauthors.

For now, PRoXe includes only blood cancers, which are easier to biopsy and successfully transplant than solid tumors. But Weinstock noted in the press release that he and his colleagues are now in talks with several universities to expand the repository to include other biopsy tissues.

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

Overcoming the Efficiency Challenge in Clinical NGS
Overcoming the Efficiency Challenge in Clinical NGS
Download this white paper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QIAGEN Clinical Insight (QCI) Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%!
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas, Inc., an emerging diagnostic company, launched a portfolio of products that can improve the accuracy of current diagnostic test results by helping laboratory professionals detect and manage biotin interference in patient samples with VeraTest Biotin and VeraPrep Biotin.
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
Scientists presented more than 30 abstracts featuring Bio-Rad’s Droplet Digital PCR (ddPCR) technology at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31–June 4.
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
The National Institute Of Allergy And Infectious Disease recently awarded BellBrook Labs a $300,000 Small Business Innovative Research (SBIR) grant to develop novel inhibitors for the target cyclic GAMP Synthase (cGAS). The grant will be used to accelerate the discovery of new treatments for autoimmune diseases by targeting the cGAS-STING pathway.